Title | Tumor expression of adiponectin receptor 2 and lethal prostate cancer. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S |
Corporate Authors | Transdisciplinary Prostate Cancer Partnership(ToPCaP) |
Journal | Carcinogenesis |
Volume | 36 |
Issue | 6 |
Pagination | 639-47 |
Date Published | 2015 Jun |
ISSN | 1460-2180 |
Keywords | Adiponectin, Adult, Aged, Aged, 80 and over, Apoptosis, Biomarkers, Tumor, Cell Proliferation, Disease Progression, Fatty Acid Synthase, Type I, Humans, Ki-67 Antigen, Male, Middle Aged, Neovascularization, Pathologic, Obesity, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, Receptors, Adiponectin |
Abstract | To investigate the role of adiponectin receptor 2 (AdipoR2) in aggressive prostate cancer we used immunohistochemistry to characterize AdipoR2 protein expression in tumor tissue for 866 men with prostate cancer from the Physicians' Health Study and the Health Professionals Follow-up Study. AdipoR2 tumor expression was not associated with measures of obesity, pathological tumor stage or prostate-specific antigen (PSA) at diagnosis. However, AdipoR2 expression was positively associated with proliferation as measured by Ki-67 expression quartiles (P-trend < 0.0001), with expression of fatty acid synthase (P-trend = 0.001), and with two measures of angiogenesis (P-trend < 0.1). An inverse association was observed with apoptosis as assessed by the TUNEL assay (P-trend = 0.006). Using Cox proportional hazards regression and controlling for age at diagnosis, Gleason score, year of diagnosis category, cohort and baseline BMI, we identified a statistically significant trend for the association between quartile of AdipoR2 expression and lethal prostate cancer (P-trend = 0.02). The hazard ratio for lethal prostate cancer for the two highest quartiles, as compared to the two lowest quartiles, of AdipoR2 expression was 1.9 (95% confidence interval [CI]: 1.2-3.0). Results were similar when additionally controlling for categories of PSA at diagnosis and Ki-67 expression quartiles. These results strengthen the evidence for the role of AdipoR2 in prostate cancer progression. |
DOI | 10.1093/carcin/bgv048 |
Alternate Journal | Carcinogenesis |
PubMed ID | 25863129 |
PubMed Central ID | PMC4481603 |
Grant List | CA-40360 / CA / NCI NIH HHS / United States CA-34944 / CA / NCI NIH HHS / United States HL-34595 / HL / NHLBI NIH HHS / United States P0126490 / / PHS HHS / United States CA141298 / CA / NCI NIH HHS / United States CA55075 / CA / NCI NIH HHS / United States T32 GM074897 / GM / NIGMS NIH HHS / United States 5P50CA090381-08 / CA / NCI NIH HHS / United States CA-097193 / CA / NCI NIH HHS / United States P50 CA090381 / CA / NCI NIH HHS / United States R35 CA197449 / CA / NCI NIH HHS / United States CA13389 / CA / NCI NIH HHS / United States T32 CA009001 / CA / NCI NIH HHS / United States |
Related Faculty:
Massimo Loda, M.D.